NEW YORK, Dec. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0739439/Sickle-Cell-Anemia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary GlobalData, the industry analysis specialist, has released its new report, "Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Sickle Cell Anemia Therapeutics market. The report identifies the key trends shaping and driving the global Sickle Cell Anemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Sickle Cell Anemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Scope The report provides information on the key drivers and challenges of the Sickle Cell Anemia Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Sickle Cell Anemia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Sickle Cell Anemia Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Sickle Cell Anemia Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Sickle Cell Anemia Therapeutics market

Reasons to buy The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Sickle Cell Anemia Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Sickle Cell Anemia Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Sickle Cell Anemia Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Sickle Cell Anemia Therapeutics - Introduction 7

2.1 Disease Overview 7

2.2 Epidemiology 9

2.3 Etiology 9

2.4 Symptoms 10

2.5 Risk Factors 10

2.6 Diagnosis 11

2.7 Treatment and Management Pattern 12

2.8 GlobalData Pipeline Report Guidance 13

3 Sickle Cell Anemia Therapeutics - Market Characterization 14

3.1 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Global 14

3.2 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Global 16

3.3 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - the US 18

3.4 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - the US 19

3.5 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - the UK 20

3.6 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - the UK 21

3.7 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - France 22

3.8 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - France 23

3.9 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Germany 24

3.10 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Germany 25

3.11 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Italy 26

3.12 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Italy 27

3.13 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Spain 28

3.14 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Spain 29

3.15 Sickle Cell Anemia Therapeutics Market Size (2005-2010) and Forecast (20102018) - Japan 30

3.16 Drivers and Barriers for Sickle Cell Anemia 31

3.16.1 Drivers for the Sickle Cell Anemia Therapeutics Market 31

3.16.2 Barriers for the Sickle Cell Anemia Therapeutics Market 31

3.17 Opportunity and Unmet Needs 33

3.18 Key Takeaway 33

4 Sickle Cell Anemia Therapeutics Market - Competitive Assessment 34

4.1 Overview 34

4.1.1 Strategic Competitor Assessment 34

4.2 Product Profiles for the Major Products in Sickle Cell Anemia 35

4.2.1 Hydroxyurea 35

4.2.2 Penicillin V 36

4.3 Key Takeaway 36

5 Sickle Cell Anemia Therapeutics - Pipeline Assessment 37

5.1 Overview 37

5.2 Strategic Pipeline Assessment 37

5.3 Pipeline Analysis by Phase of Development 38

5.3.1 Sickle Cell Anemia Therapeutics - Phase II / III Pipeline 38

5.3.2 Sickle Cell Anemia Therapeutics - Phase II Pipeline 38

5.3.3 Sickle Cell Anemia Therapeutics - Phase I/II Pipeline 39

5.3.4 Sickle Cell Anemia Therapeutics - Phase I Pipeline 39

5.3.5 Sickle Cell Anemia Therapeutics - Preclinical Pipeline 39

5.3.6 Sickle Cell Anemia Therapeutics - Discovery Pipeline 39

5.4 Sickle Cell Anemia Therapeutics: Pipeline by Mechanism of Action 40

5.5 Sickle Cell Anemia Therapeutics - Other Promising Mechanisms of Action 41

5.6 Technology Trends Analytic Framework 41

5.7 Molecule Profile for Drugs under Phase II Clinical Development 43

5.7.1 Varespladib sodium (A-001) 43

5.7.2 Exjade (deferasirox, ICL670) 44

5.7.3 GMI-1070 45

5.7.4 HQK-1001 45

5.8 Key Takeaway 46

6 Sickle Cell Anemia Therapeutics - Clinical Trials Mapping 47

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 47

6.2 Clinical Trials by Phase 48

6.3 Clinical Trials by Trial Status 49

6.4 Prominent Sponsors 50

6.5 Top Sponsors Participating in Sickle Cell Anemia Therapeutics Clinical Trials 52

7 Sickle Cell Anemia Therapeutics - Strategic Assessment 53

7.1 Future Market Competition Scenario 53

8 Sickle Cell Anemia Therapeutics - Future Players 54

8.1 Introduction 54

8.2 Company Profiles for the Promising and Marketed Drugs 55

8.2.1 Anthera Pharmaceuticals Inc. (Anthera) 55

8.2.2 Novartis Pharmaceuticals 56

8.2.3 GlycoMimetics, Inc. 58

8.2.4 Pfizer 59

8.2.5 HemaQuest Pharmaceuticals Inc. 61

8.3 Other Companies in the Sickle Cell Anemia Market, 2011 62

9 Sickle Cell Anemia Therapeutics - Licensing and Partnership Deals 63

10 Sickle Cell Anemia Therapeutics - Appendix 65

10.1 Market Definitions 65

10.2 Abbreviations 65

10.3 Methodology 66

10.3.1 Coverage 66

10.3.2 Secondary Research 66

10.3.3 Forecasting 67

10.3.4 Primary Research 70

10.3.5 Expert Panel Validation 70

10.4 Contact Us 70

10.5 Disclaimer 70

10.6 Bibliography 71

 

List of Tables

 

 

Table 1: Prevalence of Sickle Cell Anemia in Major Markets in 2011 9

Table 2: Sickle Cell Anemia Therapeutics Market, Global, Revenue ($m), 2005-2010 14

Table 3: Sickle Cell Anemia Therapeutics Market, Global, Market Forecast ($m), 2010-2018 16

Table 4: Sickle Cell Anemia Therapeutics Market, the US, Revenue($m), 2005-2010 18

Table 5: Sickle Cell Anemia Therapeutics Market, the US, Market Forecast ($m), 2010-2018 19

Table 6: Sickle Cell Anemia Therapeutics Market, the UK, Revenue ($m), 2005-2010 20

Table 7: Sickle Cell Anemia Therapeutics Market, the UK, Market Forecast ($m), 2010-2018 21

Table 8: Sickle Cell Anemia Therapeutics Market, France, Revenue ($m), 2005-2010 22

Table 9: Sickle Cell Anemia Therapeutics Market, France, Market Forecast ($m), 2010-2018 23

Table 10: Sickle Cell Anemia Therapeutics Market, Germany, Revenue ($m), 2005-2010 24

Table 11: Sickle Cell Anemia Therapeutics Market, Germany, Market Forecast ($m),2010-2018 25

Table 12: Sickle Cell Anemia Therapeutics Market, Italy, Revenue ($m), 2005-2010 26

Table 13: Sickle Cell Anemia Therapeutics Market, Italy, Market Forecast ($m), 2010-2018 27

Table 14: Sickle Cell Anemia Therapeutics Market, Spain, Revenue ($m), 2005-2010 28

Table 15: Sickle Cell Anemia Therapeutics Market, Spain, Market Forecast ($m), 2010-2018 29

Table 16: Efficacy results of hydroxyurea for adults with sickle cell anemia 35

Table 17: Safety results of hydroxyurea for adults with sickle cell anemia 35

Table 18: Sickle Cell Anemia Therapeutics - Phase II / III Pipeline, 2011 38

Table 19: Sickle Cell Anemia Therapeutics - Phase II Pipeline, 2011 38

Table 20: Sickle Cell Anemia Therapeutics - Phase I/II Pipeline, 2011 39

Table 21: Sickle Cell Anemia Therapeutics - Phase I Pipeline, 2011 39

Table 22: Sickle Cell Anemia Therapeutics - Preclinical Pipeline, 2011 39

Table 23: Sickle Cell Anemia Therapeutics - Discovery Pipeline, 2011 39

Table 24: Sickle Cell Anemia Therapeutics - Other Promising Mechanisms of Action 41

Table 25: Adverse Effects Due to Deferasirox 44

Table 26: Sickle Cell Anemia Therapeutics - Clinical Mapping by Region / Country, 2011 47

Table 27: Sickle Cell Anemia Therapeutics - Clinical Mapping by Phase, 2011 48

Table 28: Sickle Cell Anemia Therapeutics - Clinical Mapping by Trial Status, 2011 49

Table 29: Sickle Cell Anemia Therapeutics - Clinical Mapping by Overall Sponsors, 2011 50

Table 30: Sickle Cell Anemia Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 51

Table 31: Sickle Cell Anemia Therapeutics - Clinical Mapping by Top Sponsors, 2011 52

Table 32: Anthera Pharmaceuticals - Pipeline Products, 2011 55

Table 33: Anthera Pharmaceuticals - Sickle Cell Anemia Pipeline Product, 2011 55

Table 34: Novartis Pharmaceuticals - Pipeline Products, 2011 57

Table 35: Novartis Pharmaceuticals - Sickle Cell Anemia Pipeline Product, 2011 58

Table 36: Glyco Mimetics Inc.- Pipeline Products, 2011 58

Table 37: Glyco Mimetics Inc.- Sickle Cell Anemia Pipeline Product, 2011 58

Table 38: HemaQuest Pharmaceuticals Inc. - Pipeline Product, 2011 61

Table 39: HemaQuest Pharmaceuticals Inc. - Sickle Cell Anemia Pipeline Product, 2011 61

Table 40: Sickle Cell Anemia Therapeutics - Future Players, 2011 62

Table 41: Sickle Cell Anemia Therapeutics, Global, Deals 63

 

List of Figures

 

 

Figure 1: Pictorial Representation of Normal and Abnormal Red Blood Cells 7

Figure 2: Inheritance Pattern of Sickle Cell Trait 8

Figure 3: Types of Sickle Cell Disease 8

Figure 4: Symptoms of Sickle Cell Anemia 10

Figure 5: Complications of Sickle Cell Anemia 11

Figure 6: Sickle Cell Anemia Therapeutics Market, Global, Revenue ($m), 2005-2010 14

Figure 7: Sickle Cell Anemia Therapeutics , Market Share (%), 2010 15

Figure 8: Sickle Cell Anemia Therapeutics Market, Global, Market Forecast ($m), 2010-2018 16

Figure 9:Sickle Cell Anemia Therapeutics, Market Share (%), 2018 17

Figure 10: Sickle Cell Anemia Therapeutics Market, the US, Revenue ($m), 2005-2010 18

Figure 11: Sickle Cell Anemia Therapeutics Market, the US, Market Forecast ($m), 2010-2018 19

Figure 12: Sickle Cell Anemia Therapeutics Market, the UK, Revenue ($m), 2005-2010 20

Figure 13: Sickle Cell Anemia Therapeutics Market, the UK, Market Forecast ($m), 2010-2018 21

Figure 14: Sickle Cell Anemia Therapeutics Market, France, Revenue ($m), 2005-2010 22

Figure 15: Sickle Cell Anemia Therapeutics Market, France, Market Forecast ($m), 2010-2018 23

Figure 16: Sickle Cell Anemia Therapeutics Market, Germany, Revenue ($m), 2005-2010 24

Figure 17: Sickle Cell Anemia Therapeutics Market, Germany, Market Forecast ($m), 2010-2018 25

Figure 18: Sickle Cell Anemia Therapeutics Market, Italy, Revenue ($m), 2005-2010 26

Figure 19: Sickle Cell Anemia Therapeutics Market, Italy, Market Forecast ($m), 2010-2018 27

Figure 20: Sickle Cell Anemia Therapeutics Market, Spain, Revenue ($m), 2005-2010 28

Figure 21: Sickle Cell Anemia Therapeutics Market, Spain, Market Forecast ($m), 2010-2018 29

Figure 22: Sickle Cell Anemia Therapeutics Market, Quotes from Japanese Hematologists 30

Figure 23: Sickle Cell Anemia Therapeutics - Drivers and Barriers, 2011 32

Figure 24: Opportunity and Unmet Need for adults in Sickle Cell Anemia Therapeutics Market, 2011 33

Figure 25: Strategic Competitor Assessment of Sickle Cell Anemia Therapeutics Market, 2011 34

Figure 26: Sickle Cell Anemia Therapeutics Pipeline by Phase of Clinical Development, 2011 38

Figure 27: Sickle Cell Anemia Therapeutics - Clinical Pipeline by Mechanism of Action, 2011 40

Figure 28: Technology Trends Analytic Framework of the Sickle Cell Anemia Therapeutics Pipeline, 2011 42

Figure 29: Technology Trends Analytic Framework of the Sickle Cell Anemia Therapeutics Pipeline - Description, 2011 43

Figure 30: Sickle Cell Anemia Therapeutics - Clinical Mapping by Region / Country, 2011 47

Figure 31: Sickle Cell Anemia Therapeutics - Clinical Mapping by Phase, 2011 48

Figure 32: Sickle Cell Anemia Therapeutics - Clinical Mapping by Trial Status, 2011 49

Figure 33: Sickle Cell Anemia Therapeutics - Clinical Mapping by Overall Sponsors, 2011 50

Figure 34: Sickle Cell Anemia Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 51

Figure 35: Sickle Cell Anemia Therapeutics - Clinical Mapping by Top Sponsors, 2011 52

Figure 36: Sickle Cell Anemia Therapeutics - Implications for Future Market Competition, 2011 53

Figure 37: Sickle Cell Anemia Therapeutics - Clinical Pipeline by Company, 2011 54

Figure 38: GlobalData Market Forecasting Model 69

 

Companies mentioned

 

Anthera Pharmaceuticals Inc. (Anthera)

Novartis Pharmaceuticals

GlycoMimetics, Inc.

Pfizer

HemaQuest Pharmaceuticals Inc.

To order this report:Therapy Industry: Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com